Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (DE:EVL)
FRANKFURT:EVL
EVL Stock Chart & Stats
€5.50
-€0.10(-0.96%)
At close: 4:00 PM EST
€5.50
-€0.10(-0.96%)
Day’s Range― - ―
52-Week Range€5.00 - €14.20
Previous CloseN/A
Volume0.00
Average Volume (3M)115.00
Market Cap
$381.75M
Enterprise Value€508.79M
Total Cash (Recent Filing)$43.52M
Total Debt (Recent Filing)$180.77M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding64,685,420
10 Day Avg. Volume0
30 Day Avg. Volume115
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)123.99
Price to Sales (P/S)2.57
P/FCF Ratio-35.16
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-12.00
Forecast
1Y Price Target
$16.92Price Target Upside207.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market StrategyEvolus' ability to grow despite the broader market coming under pressure is a testament to its go-to market strategy and its positioning for when the market does improve.
Profitability ProjectionManagement remains confident in achieving profitability, with a projected non-GAAP operating income of $5 million to $7 million in 4Q.
Revenue GuidanceManagement reaffirmed its net revenue guidance for 2025, expecting between $295 million and $305 million given solidifying performance for Jeuveau and a strong launch for Evolysse.
Bears Say
Consumer SentimentContinuing macro pressures and negative consumer sentiment are weighing down on the aesthetics market, restricting growth of toxins and fillers.
Macroeconomic ChallengesManagement cautioned about potential impacts from a soft macroeconomic environment and tariffs.
Revenue Target UncertaintyManagement's 2028 revenue 'target' of $700M is an overhang, creating uncertainty among investors.
Evolus News
EVL FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was €5.00 and its highest was €14.20 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $381.75M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Mar 11, 2026 which is in 122 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Nov 05, 2025. The company reported -€0.114 earnings per share for the quarter, beating the consensus estimate of -€0.141 by €0.027.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is 0.05.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,685,420 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -€0.114 in its last earnings report, beating expectations of -€0.141. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in DE:EVL
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.92 (207.59% Upside)
$16.92 (207.59% Upside)
Blogger Sentiment
Bullish
DE:EVL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $204.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EVL Company Deck
EVL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call depicted both strong achievements, particularly with the successful launch of Evolysse and international expansion, and significant challenges, including decreased demand for Jeuveau and a challenging market environment. While there are optimistic signs for the future, such as expected improvements in demand and strategic cost optimizations, the immediate outlook is hindered by current market conditions.View all DE:EVL earnings summariesEVL Stock 12 Month Forecast
Average Price Target
€16.92
▲(207.59% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Options Prices
Currently, No data available
---